Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) price on Friday, April 11, rose 3.19% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $317.15.
A look at the stock’s price movement, the close in the last trading session was $307.35, moving within a range at $304.06 and $324.14. The beta value (5-Year monthly) was -0.695. Turning to its 52-week performance, $377.46 and $189.00 were the 52-week high and 52-week low respectively. Overall, MDGL moved -1.82% over the past month.
Madrigal Pharmaceuticals Inc’s market cap currently stands at around $7.00 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-25.
Analysts have a consensus estimate of 112.79M for the company’s revenue for the quarter, with a low and high estimate of 96.82M and 132M respectively. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 587M, representing a 225.87% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MDGL is a Hold. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
11 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 9 recommend MDGL as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MDGL’s current price about -3.46% and -4.45% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.24, while 7-day volatility ratio is 9.45% and 5.57% in the 30-day chart. Further, Madrigal Pharmaceuticals Inc (MDGL) has a beta value of -0.82, and an average true range (ATR) of 19.91. Analysts have given the company’s stock an average 52-week price target of $355.5, forecast between a low of $111 and high of $410. Looking at the price targets, the low is 65.0% off current price level while to achieve the yearly target high, price needs to move -29.28%. Nonetheless, investors will most likely welcome a -12.09% jump to $355.5 which is the analysts’ median price.
If we refocus on Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), historical trading data shows that trading volumes averaged 0.38 over the past 10 days and 411.70K over the past 3 months. The company’s latest data on shares outstanding shows there are 22.00 million shares.
The 9.67% of Madrigal Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 104.01% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.09 million on 2025-03-14, giving us a short ratio of 8.96. The data shows that as of 2025-03-14 short interest in Madrigal Pharmaceuticals Inc (MDGL) stood at 2647.0 of shares outstanding, with shares short rising to 3.8 million registered in 2025-02-14. Current price change has pushed the stock 2.78% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MDGL stock continues to rise going into the next quarter.
